



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/20	A1	(11) International Publication Number: WO 98/08501 (43) International Publication Date: 5 March 1998 (05.03.98)
(21) International Application Number: PCT/GB97/02282 (22) International Filing Date: 26 August 1997 (26.08.97) (30) Priority Data: 9617847.0 27 August 1996 (27.08.96) GB (71) Applicant (for all designated States except US): SCOTIA HOLDINGS PLC [GB/GB]; Weyvern House, Weyvern Park, Portsmouth Road, Peasmarsh, Guildford, Surrey GU3 1NA (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): HORROBIN, David, Frederick [GB/GB]; Scotia Holdings plc, Scotia House, Castle Business Park, Stirling FK9 4TZ (GB). STORDY, Barbara, Jacqueline [GB/GB]; Scotia Pharmaceuticals Ltd., Weyvern House, Weyvern Park, Portsmouth Road, Peasmarsh, Guildford, Surrey GU3 1NA (GB). (74) Agent: FARWELL, William, Robert; Philips & Leigh, 7 Staple Inn, Holborn, London WC1V 7QF (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: USE OF ARACHIDONIC ACID AND/OR DOCOSAHEXANOIC ACID FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DYSPRAXIA		
(57) Abstract Use of AA or DHA, desirably both, or in either case one or more precursor fatty acids, for the preparation of a medicament for treatment (including prophylaxis), by administration to children or pregnant women of dyspraxic or, specifically, poor fine and gross motor skills in dyspraxia or alternatively poor fine and gross motor skills in non-dyspraxic individuals, and such treatment and medicament in themselves.		

USE OF ARACHIDONIC ACID AND/OR DOCOSAHEXANOIC ACID FOR THE MANUFACTURE
OF A MEDICAMENT FOR THE TREATMENT OF DYSPRAXIA

FIELD OF INVENTION

This invention relates to fatty acids and their use.

GENERAL

Dyspraxia or apraxia, is a problem of human development, giving difficulty in planning and carrying out skilled non-habitual motor acts in the correct sequence (Fisher, Murray & Bundy, 1991). It is an impairment or immaturity of the organisation of movement, associated with which there may be problems of language, perception and thought. (Dyspraxia Trust 1995). Several different terms have been used to describe this disorder, Developmental Dyspraxia, Clumsy Child Syndrome, Minimal Brain Dysfunction, Perceptual Motor Dysfunction, Sensory Integrative Dysfunction, Motor Learning Difficulty, Apraxia, and Development Co-ordination Disorder. The term used in the Diagnostic and Statistical Manual of Mental Disorders DSM IV Washington, D.C. (American Psychiatric Association 1994) is Developmental Co-ordination Disorder., The World Health Organisation International Classification of Diseases Code (ICD-9-CM) is 315.4.

Dyspraxia is now recognised to be caused by an immaturity of brain development associated with poor synaptic transmission and possibly poor arborisation of neurones, that is to say a disorder with an organic basis.

In practical terms dyspraxics are poorly co-ordinated, disorganised, have problems of ideation, motor planning and execution so that written work and ball games are extremely difficult for them. Handwriting is poor. Poor memory, restlessness and impulsiveness may be features of the condition. Poor peer relations as a consequence of their clumsiness and slow learning of games lead to low self esteem.

PRESENT WORK

The invention is discussed in general terms later herein but broadly we have found dyspraxia to be due to inadequate supplies of the long chain polyunsaturated fatty acids docosahexaenoic acid (DHA) and arachidonic acid (AA). Dyspraxia may thus be treated by providing DHA and AA, the earlier the better. LA and especially GLA and DGLA are metabolic precursors of AA, and may be used in its stead. Likewise ALA and especially SA and EPA are precursors of DHA and may be used in its stead. Antioxidants may optionally be provided as well since they protect the highly polyunsaturated fatty acids and increase their incorporation into cell membranes.

DHA and AA are major constituents of the retina, of nerve tissue and of the brain. DHA is found in high concentrations at synapses and AA is important for cell signalling. Recent work has shown that their provision to children is important in the normal development of visual acuity, dark adaptation and cognitive function and is of particular benefit for dyslexics. However to our knowledge no one has previously suggested that dyspraxic individuals might also benefit from this treatment approach.

We first found a dramatic response to treatment with AA, DHA and GLA in a boy with dyspraxia. The subject was a 5 year old boy with severe dyspraxia. He exhibited all the classic signs of dyspraxia, he was clumsy, had poor balance and consequently bumped into objects and was accident prone. His drinks were always provided in a cup with a lid and a straw because of spillage. He did not enjoy and avoided drawing or learning to write because of poor fine motor skills and the difficulty of holding a pencil and physically drawing the lines as he wished. He had similar difficulty with scissors and cutting out. Clumsiness in ball games and difficulty with catching and hitting a ball lead to poor self esteem and difficulties in playing with friends. Characteristically at school he avoided the tasks which involved reading and writing and was easily distracted in class.

After supplementation with essential fatty acids and antioxidant for two months, his fine and gross motor skills and balance had improved so much that he rarely tripped over, he

marked degree of movement difficulty. Such children require further monitoring and assessment and may need immediate intervention. Children who fall on or below the 5th percentile required detailed assessment and special consideration in terms of management and remediation programmes.

The objective measures of manual dexterity, ball skills and static and dynamic balance are summed to derive the Total Impairment Score (TIS). Percentile norms for TIS are used to assess severity of impairment. The cut off points are similar to those for the check list, 5th and 15th percentiles. If children fall on or below these percentiles intervention and remediation programs are required.

At the outset all children had checklist scores below the 15th percentile indicating a marked degree of movement difficulty. This was confirmed by the objective measures of movement performance, Table 2. The Total Impairment Score, derived by summing scores for manual dexterity, ball skills and static and dynamic balance was below the 1st percentile for 14 children and one child, age 12, was on the 8th percentile. Scores are interpreted in forms of the norms expressed as percentiles. High scores in the table indicate poor performance. Manual dexterity, ball skills and static and dynamic balance were poor at baseline and improved following supplement (Table 2). Overall Total Impairment Scores and Check list scores improved significantly following supplementation (Table 2).

The parents completed a behaviour rating scale (Conners) for their children. There was evidence of reduced anxiety and improved behaviour following fatty acid supplementation (Table 3).

Table 2

ABC Movement Assessment Scores* (Mean \pm SD) in 15 dyspraxic children before and after four months supplementation with n-3 and n-6 fatty acids

	Before	After	Paired t-test
Manual dexterity	93 \pm 2.85	6.95 \pm 3.76	<0.007
Ball Skill	6.03 \pm 2.94	3.90 \pm 2.13	<0.002
Static and dynamic balance	8.23 \pm 4.47	5.88 \pm 4.09	<0.03
Total impairment score	24.20 \pm 6.83	16.73 \pm 8.16	<0.0001
Check list*	87.14 \pm 29.61	65.07 \pm 28.63	<0.001

treatment, we propose the approach as preventive in at risk situations by administration of fatty acids to children as babies or to their mothers in pregnancy.

Although AA and DHA are key fatty acids for the nerves and brain, the other n-6 and n-3 fatty acids derived from linoleic acid and alpha-linolenic acid (Table 1) are also important in these tissues. Because DHA and EPA (which is usually associated with DHA in fish oils) can inhibit conversion of linoleic to gamma-linolenic acid (GLA), it may be appropriate to provide with the DHA and AA, in some situations, supplements of GLA and/or DGLA as well, to prevent depletion of these important fatty acids. It may also be appropriate to provide EPA with the DHA. Furthermore the provision of antioxidants with the DHA and AA to protect the stability of the fatty acids in vivo may be appropriate. Some beneficial effects may accrue from giving either n-6 EFAs or n-3 EFAs alone, but because of the importance of both types of EFA in the central nervous system, both types, given together, are likely to give better results.

FORMS AND AMOUNTS

The fatty acids may be delivered in any appropriate form which can raise the levels of DHA, AA and /or the other fatty acids in the blood plasma and reference to fatty acids includes reference to them in such forms. Appropriate forms are the free fatty acids, their salts, including lithium salts, esters, amides alcohols, tri-, di- and monoglycerides, ascorbyl, meglumine and niacin derivatives, diesters and phospholipids such as phosphatidylcholine or phosphatidyl-ethanolamine or any other appropriate carrier.

The fatty acids are not toxic and so they may be given in doses of from 1mg to 100g per day, preferably 20mg to 10g and very preferably 50mg to 2g/day, formulations suitably being provided to give convenient divided doses. They may be administered orally, enterally, parenterally or topically by any appropriate formulation including fortification of conventional foods, capsules, pastilles, tablets, powders, emulsions, suspensions, oils, creams, lotions, patches, liposomes, galactolipid based preparations or any other form known to those skilled in the art.

CLAIMS

1. Use of AA or DHA, desirably both, or in either case one or more precursor fatty acids, for the preparation of a medicament for treatment (including prophylaxis), by administration to children or pregnant women, of dyspraxia or poor fine and gross motor skills specifically in dyspraxia or alternatively poor fine and gross motor skills in non-dyspraxic individuals, and such treatment and medicament in themselves.
2. As 1, specifically for prophylaxis in children between birth and the age of one year.
3. As 1 or 2, wherein the precursor acids are selected from LA and preferably GLA and DGLA for AA, and ALA and preferably SA and EPA for DHA.
4. As 1 or 2, specifically with GLA or DGLA in addition to AA.
5. As 1 to 4, with in addition, a pharmaceutically acceptable antioxidant for the fatty acids.